Covid-19 related prescribing guidance
General Guidance
General Medicines-Related Issues
Teamnet COVID-19 Resources for Practices
Please click here for PSNC summary of updates and guidance relating to community pharmacy and COVID-19
Please click here for University of Liverpool COVID-19 drug interaction checker tool
Please click here for Primary Care advice for immunosuppression in Covid-19 patients
Yellow Card Reporting
The MHRA have launched a dedicated Yellow Card reporting site for healthcare products that are used in Coronavirus (COVID-19) treatment to be easily reported: coronavirus-yellowcard.mhra.gov.uk
Healthcare professionals, patients and carers are asked to report all suspected side effects to medicines or medical device adverse incidents related to COVID-19 treatment. This also includes medicines that patients and healthcare professionals are using off-label to treat COVID-19. Reporting will enable the MHRA to rapidly identify new and emerging side effects and medical device issues which may not have been previously known about, including diagnostic tests for COVID-19. This includes any medicines taken by patients to manage long-term, or pre-existing conditions that may influence the disease or have any potential interactions.
High Risk Drug Monitoring
The Covid-19 High Risk Drug Monitoring Guidance has now been withdrawn as it is now appropriate to return use of Shared Care Protocols for monitoring guidance. This decision is supported by UHBW, NBT and AWP.
Care Homes
Please click here for the good practice guide from the British Geriatrics Society (BGS) on Managing the COVID-19 pandemic in care homes.
Please click here for guidance on Medicines Optimisation Support to Care Homes in the event of a COVID-19 outbreak
Sick Day Rules
Please click here for BNSSG guidance on sick day rules (preventing dehydration during periods of acute illness)
Medicines Delivery to patients during COVID-19
Please click here for GP referral pathways into the voluntary community social enterprise (VCSE) sector
Gastro-intestinal system
Inflammatory Bowel Disease
Please click here for advice from International Organization for the study of Inflammatory Bowel Disease during the COVID-19 outbreak.
Please click here for patient advice from Crohn's and Colitis UK during the COVID-19 outbreak.
Please click here for advice from British Society of Gastroenterology on use of immunosuppression during the COVID-19 outbreak.
Please click here for NICE COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response.
Cardiovascular System
ACEi/ARBs
Please click here for the MHRA alert regarding high blood pressure medication during the COVID-19 outbreak.
Please click here for the British Cardiovascular Society and British Society for Heart Failure's joint statement on use of ACEi and ARBs during the COVID-19 outbreak.
Please click here for the European Society of Cardiology's guidance on ACEi and ARBs during the COVID-19 outbreak.
Anticoagulation
Please click here for the NHSE advice regarding anticoagulation during the COVID-19 outbreak
Please see BNSSG COVID-19: Coagulopathy, Thrombosis prevention and DIC
Respiratory System
Please click here for information, guidance and resources from the British Thoracic Society (BTS) to support the respiratory community during the COVID-19 pandemic
Please click here for NICE Managing COVID-19.
Central Nervous System
Analgesia
NSAIDs
Please click here for CAS alert for the NHSE message regarding use of ibuprofen during the COVID-19 outbreak. (14/4/2020)
Please click here for NICE evidence summary on the use of ibuprofen during the COVID-19 outbreak (14/4/20)
Multiple Sclerosis
Please click here for the Association of British Neurologists (ABN) guidance on the use of Disease Modifying Therapies (DMARDs) during the COVID-19 outbreak.
Mental Health
Please click here to visit Avon and Wiltshire Mental Health Partnership (AWP) website for further information
Please click here for BNSSG Mental wellbeing toolkit during COVID-19 leaflet
Sodium Valproate
The MHRA have provided temporary advice for the 'Valproate Pregnancy Prevention Programme' during the Coronavirus (COVID-19) pandemic - available here
Endocrine
Diabetes
Please click here for Primary Care Diabetes Society guidance on managing diabetes during the COVID-19 outbreak.
Obstetrics and Gynaecology
Contraception
Please click here for specific advice from Faculty of Sexual and Reproductive Health (FSRH) regarding provision of effective contraception during the COVID-19 outbreak.
Update, The Faculty of Sexual and Reproductive Healthcare (FSRH) makes recommendations relating to contraceptive services at times when lockdown restrictions are eased. It is anticipated that following the current period of Covid-19 lockdown, there will be an ongoing requirement for social distancing. Please click here for advice.
Malignant Disease and Immunosuppression
Rheumatology
Please click here for COVID-19 guidance from British Society of Rheumatology
Please click here for guidance from British Society of Rheumatology on identifying high risk patients on immunosuppression during the COVID-19 outbreak and please click here for their guidance on management of patients on corticosteroids.
There is also a local guideline available on blood monitoring for High Risk Drugs during Covid-19 which includes local recommendations on monitoring of immunosuppressants during Covid-19. Please click here for BNSSG Blood Monitoring for High Risk drugs during COVID-19 guidance.
Please click here for NICE COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders. This guidance links to the Society of Endocrinology's advice on managing adrenal crisis during COVID-19
Renal Disease
Please click here for patient advice from Kidney Care UK during the COVID-19 outbreak.
Please click here for NICE COVID-19 rapid guideline: chronic kidney disease.
Systemic Anti-cancer treatments
Please click here for NICE rapid guideline on delivery of systemic anticancer treatments during COVID-19 outbreak.
Dermatology
Please click here for statement from International Psoriasis Council on immunosuppressant medications during the COVID-19 outbreak.
Please click here for a Safe Prescribing and Monitoring Protocol for Systemic immunomodulatory therapies for immune-mediated inflammatory skin disease in the context of Coronavirus (COVID-19).
Note - there is a local guideline available on blood monitoring for High Risk Drugs during Covid-19 which includes local recommendations on monitoring of immunosuppressants during Covid-19. Please click here for BNSSG Blood Monitoring for High Risk drugs during COVID-19 guidance.